A cost minimization analysis of first-line polychemotherapy regimens in the treatment of advanced non-small cell lung cancer

被引：0
|
作者：
Le Lay, K
Avoinet, S
Chemali, N
Vergnenegre, A
Launois, R
机构：
[1] REES France, Paris, France
[2] Lilly France, F-92158 Suresnes, France
[3] CHU Limoges, Serv Informat Med, F-87042 Limoges, France
[4] Univ Paris 13, F-93017 Bobigny, France
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S255 / S255
页数：1
相关论文
共 50 条
  • [41] Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer
    Waterhouse, David
    Lam, Jenny
    Betts, Keith A.
    Yin, Lei
    Gao, Sophie
    Yuan, Yong
    Hartman, John
    Rao, Sumati
    Lubinga, Solomon
    Stenehjem, David
    [J]. LUNG CANCER, 2021, 156 : 41 - 49
  • [42] Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer
    Syrigos, K.
    Charpidou, A.
    Grapsa, D.
    Vassos, D.
    Tsimpoukis, S.
    Tsagouli, S.
    Gkiozos, I.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S902 - S903
  • [43] Real-World Outcomes of Immunotherapy-Based Regimens in First-Line Advanced Non-Small Cell Lung Cancer
    Waterhouse, D.
    Lam, J.
    Betts, K. A.
    Yin, L.
    Gao, S.
    Yuan, Y.
    Hartman, J.
    Rao, S.
    Lubinga, S.
    Stenehjem, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S17 - S18
  • [44] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Aguiar, Pedro N., Jr.
    Haaland, Benjamin
    Park, Wungki
    Tan, Pui San
    del Giglio, Auro
    Lopes, Gilberto de Lima, Jr.
    [J]. JAMA ONCOLOGY, 2018, 4 (08) : 1080 - 1084
  • [45] First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
    Lee, Young Joo
    Kim, Heung Tae
    Han, Ji-Youn
    Yun, Tak
    Lee, Geon Kook
    Kim, Hyae Young
    Sung, Ji-Hyun
    Lee, Jin Soo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 361 - 368
  • [46] A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
    Cuc Thi Thu Nguyen
    Fabio Petrelli
    Stefania Scuri
    Binh Thanh Nguyen
    Iolanda Grappasonni
    [J]. The European Journal of Health Economics, 2019, 20 : 763 - 777
  • [47] A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
    Cuc Thi Thu Nguyen
    Petrelli, Fabio
    Scuri, Stefania
    Binh Thanh Nguyen
    Grappasonni, Iolanda
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (05): : 763 - 777
  • [48] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS NIVOLUMAB AS THE FIRST-LINE TREATMENT FOR ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER IN UNITED KINGDOM
    Verma, J.
    Verma, D.
    Maria, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S41 - S41
  • [49] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin1
    [J]. The Journal of Biomedical Research, 2009, (06) : 392 - 397
  • [50] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
12345